Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | S100A4 | P26447 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19600443 | 0.80 | CXCR2 (0.46) | S100A4CA1CA2ALDH1A1CYP3A4 | |
| SCHEMBL16282222 | 0.79 | S100A4 (0.39) | S100A4CA1CA2AHRGPR3 | |
| SCHEMBL16282203 | 0.78 | CRHR1 (0.44) | CRHR1ALDH1A1CYP3A4 | |
| SCHEMBL18000003 | 0.78 | CRHR1 (0.44) | CRHR1ALDH1A1CYP3A4 | |
| SCHEMBL29719717 | 0.78 | NOTUM (0.53) | GRM2NOTUMS100A4CYP3A4AHR | |
| SCHEMBL24972563 | 0.77 | S100A4 (0.46) | S100A4ALDH1A1KDM4ERXFP1 | |
| SCHEMBL30223443 | 0.77 | S100A4 (0.46) | S100A4ALDH1A1KDM4ERXFP1 | |
| SCHEMBL30984364 | 0.77 | NPC1 (0.49) | GRM2CRHR1NOTUMS100A4ALDH1A1 | |
| SCHEMBL3743600 | 0.77 | CYP1A2 (0.59) | ALDH1A1KDM4ERXFP1 | |
| SCHEMBL13176936 | 0.77 | NPC1 (0.49) | GRM2CRHR1NOTUMS100A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9991452-B2 | Condensed-cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-06-05 | — | — | US | disclosed |
| US-20160190448-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160190448-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CCNT1, CCNE2, CRY1 | GRM2 1679/4885CRHR1 270/4885NOTUM 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.